JP2005526790A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526790A5
JP2005526790A5 JP2003577900A JP2003577900A JP2005526790A5 JP 2005526790 A5 JP2005526790 A5 JP 2005526790A5 JP 2003577900 A JP2003577900 A JP 2003577900A JP 2003577900 A JP2003577900 A JP 2003577900A JP 2005526790 A5 JP2005526790 A5 JP 2005526790A5
Authority
JP
Japan
Prior art keywords
dysfunction
erectile
female sexual
female
sexual dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003577900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526790A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/008448 external-priority patent/WO2003080074A1/en
Publication of JP2005526790A publication Critical patent/JP2005526790A/ja
Publication of JP2005526790A5 publication Critical patent/JP2005526790A5/ja
Withdrawn legal-status Critical Current

Links

JP2003577900A 2002-03-19 2003-03-19 アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 Withdrawn JP2005526790A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36545402P 2002-03-19 2002-03-19
PCT/US2003/008448 WO2003080074A1 (en) 2002-03-19 2003-03-19 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof

Publications (2)

Publication Number Publication Date
JP2005526790A JP2005526790A (ja) 2005-09-08
JP2005526790A5 true JP2005526790A5 (cg-RX-API-DMAC7.html) 2006-03-09

Family

ID=28454658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003577900A Withdrawn JP2005526790A (ja) 2002-03-19 2003-03-19 アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法

Country Status (9)

Country Link
US (1) US20060004190A1 (cg-RX-API-DMAC7.html)
EP (1) EP1496915A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005526790A (cg-RX-API-DMAC7.html)
KR (1) KR20050008658A (cg-RX-API-DMAC7.html)
CN (1) CN1720054A (cg-RX-API-DMAC7.html)
AU (1) AU2003223304A1 (cg-RX-API-DMAC7.html)
BR (1) BR0308567A (cg-RX-API-DMAC7.html)
CA (1) CA2479372A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003080074A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
KR20160108828A (ko) 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
AU2015369554A1 (en) * 2014-12-23 2017-08-03 Neuroderm Ltd Crystal forms of apomorphine and uses thereof
PT3713933T (pt) 2017-11-24 2026-05-19 H Lundbeck As Novos profrmacos de catecolamina para utilizao no tratamento de doena de parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN114773409B (zh) * 2022-04-27 2023-12-15 江西艾立斯特生物科技有限公司 一种2,3,4,6-四-o-乙酰基-吡喃葡萄糖的制备方法
EP4540257A1 (en) 2022-06-15 2025-04-23 EVER Neuro Pharma GmbH Apomorphine prodrugs and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785014A (en) * 1985-06-07 1988-11-15 Yale University Use of clonidine in memory enhancement
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6266560B1 (en) * 1998-06-19 2001-07-24 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
KR20030036157A (ko) * 2000-04-07 2003-05-09 탭 파마슈티칼 프로덕츠 인코포레이티드 아포모르핀 유도체 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2004525194A5 (cg-RX-API-DMAC7.html)
JP2005519316A5 (cg-RX-API-DMAC7.html)
JP2005526058A5 (cg-RX-API-DMAC7.html)
MA26600A1 (fr) Traitement du dysfonctionnement sexuel feminin.
JP2004210767A5 (cg-RX-API-DMAC7.html)
JP2006503588A5 (cg-RX-API-DMAC7.html)
NO20033508L (no) Medikament med hurtig virkningsbegynnelse for behandling av seksuell dysfunksjon
EP1663222A4 (en) METHODS RELATING TO THE TREATMENT OF GIANCES
JP2002179603A5 (cg-RX-API-DMAC7.html)
CY1108808T1 (el) Ενωσεις μοτιλιδης
WO2005099702A3 (en) R(-)-11-hydroxyaporphine derivatives and uses thereof
GB0225908D0 (en) Treatment of female sexual dysfunction
JP2005511626A5 (cg-RX-API-DMAC7.html)
NO20024442D0 (no) Behandling av seksuell dysfunksjon med apomorfin
JP2005527457A5 (cg-RX-API-DMAC7.html)
NO20032189D0 (no) Behandling av antidepresjonsmiddel-indusert seksuell dysfunksjon med apomorfin
JP2004529205A5 (cg-RX-API-DMAC7.html)
NO20052557D0 (no) Morfolinderivater for bruk som dopamin-agonister i behandling av blant annet seksuell dysfunksjon.
AP2380A (en) Use of surfactants in the production of metal.
JP2005536763A5 (cg-RX-API-DMAC7.html)
IL163533A0 (en) Treatment of female sexual dysfunction
JP2005536335A5 (cg-RX-API-DMAC7.html)
JP2005518443A5 (cg-RX-API-DMAC7.html)
JP2005506372A5 (cg-RX-API-DMAC7.html)
GB0318706D0 (en) Selective serotonin reuptake inhibitors in the treatment of disease